Moreover, the patient’s studies illustrated the localization of Lu-177-trastuzumab at both primary and metastatic sites of HER2-positive breast cancer using the combination of Single Photon Emission Computed Tomography scan and Computed Tomography (SPECT/CT) imaging [124]. Here, ERBB2 is linked to breast carcinoma.